Versa Vascular Secures $27.3M Oversubscribed Series C Funding and Appoints David Hovda as CEO to Advance Novel Tricuspid Valve Repair Technology

Versa Vascular
Written By Guest User
Guest User
Previous

Opine Raises $5M to Build Unified AI Workspace For Complex B2B Sales
Next

Welcoming John McNamara as Avtal’s Chief Growth Officer